Association of Hyperhomocysteinemia with Increased Coronary Microcirculatory Resistance and Poor Short-Term Prognosis of Patients with Acute Myocardial Infarction after Elective Percutaneous Coronary Intervention

Table 1

Comparison of the demographic and basal clinical characteristics of patients between the two groups.

Characteristics	HHcy group (n = 53)	Control group (n = 48)		X^2 (t)
Age (years)	57.3 ± 10.9	55.9 ± 8.8	0.500	0.677
Gender, male (%)	30 (56.6%)	25 (47.2%)	0.649	0.208
BMI (kg/m^2)	27.3 ± 3.2	27.0 ± 4.0	0.696	0.391
CKD	7 (13.2%)	4 (7.5%)	0.432	0.617
Smoker	23 (43.4%)	16 (30.2%)	0.300	1.076
Hypertension	21 (39.6%)	18 (34.0%)	0.827	0.048
Diabetes mellitus	19 (35.8%)	16 (30.2%)	0.791	0.070
Dyslipidemia	24 (45.3%)	22 (45.8%)	0.956	0.003
Previous PCI	17 (32.1%)	18 (37.5%)	0.567	0.327
STEMI	48 (90.6%)	45 (93.8%)	0.554	0.350
FBG (mmol/L)	6.0 ± 1.2	5.8 ± 9.3	0.479	0.711
Cre (μmoI/L)	74.8 ± 15.3	74.6 ± 13.9	0.286	1.072
LDL-C (mmol/L)	3.1 ± 0.5	3.0 ± 0.6	0.228	1.213
HDL-C (mmol/L)	1.4 ± 0.4	1.6 ± 0.5	0.249	−1.161
CTnI (ng/ml)	0.86 ± 0.69	0.71 ± 0.35	0.191	1.316
BNP (pg/ml)	453.6 ± 124.6	393.3 ± 204.9	0.074	1.806
Hs-CRP (mg/L)	10.9 ± 1.3	9.7 ± 1.6	0.000	4.116
Medications:
Beta-blocker	38 (71.7%)	35 (72.9%)	0.891	0.019
Calcium-blocker	24 (45.3%)	20 (41.7%)	0.714	0.134
Aspirin	53 (100%)	48 (100%)	1.000
Clopidogrel	53 (100%)	48 (100%)	1.000
Atorvastatin	51 (96.2%)	47 (97.9%)	0.617	0.250
Nitrates	32 (60.4%)	30 (62.5%)	0.827	0.048
ACEI/ARB	31 (58.5%)	30 (62.5%)	0.681	0.169
Homocysteine (μmol/L)	14.15 ± 3.30	6.67 ± 1.66	0.000	14.152

HHcy: high homocysteine; BMI: body mass index; CKD: chronic kidney diseases; PCI: percutaneous coronary intervention; FBG: fasting blood glucose; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; CTnI: cardiac troponin I; Hs-CRP: high-sensitivity C-reactive protein; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.